Farnesol, a fungal quorum-sensing molecule triggers Candida Albicans morphological changes by downregulating the expression of different secreted aspartyl proteinase genes

Open Microbiology Journal

Volumn 5, Issue , 2011, Pages 119-126

  Décanis, Nadège ^a   Tazi, Neftaha ^a   Correia, Alexandra ^b   Vilanova, Manuel ^c,d   Rouabhia, Mahmoud ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b UNIVERSITY OF MINHO   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

Author keywords

Candida; Farnesol; Saps; Transition

Indexed keywords

FARNESOL; FUNGAL PROTEIN; FUNGAL RNA; MESSENGER RNA; PROTEIN SAP2; PROTEINASE; SECRETED ASPARTYL PROTEINASE 2; SECRETED ASPARTYL PROTEINASE 4; SECRETED ASPARTYL PROTEINASE 5; SECRETED ASPARTYL PROTEINASE 6; UNCLASSIFIED DRUG;

ARTICLE; CANDIDA ALBICANS; CELL VACUOLE; CELL WALL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; ENZYME INDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FUNGAL CELL; FUNGAL GENE; FUNGAL MORPHOLOGY; FUNGUS CULTURE; FUNGUS HYPHAE; GENE EXPRESSION REGULATION; MORPHOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; QUORUM SENSING; REAL TIME POLYMERASE CHAIN REACTION; SECRETED ASPARTYL PROTEINASE GENE; ULTRASTRUCTURE;

EID: 82955194847     PISSN: None     EISSN: 18742858     Source Type: Journal    
DOI: 10.2174/1874285801105010119     Document Type: Article

References (49)

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
2. Marchetti O, Bille J, Fluckiger U, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends 1991-2000. Clin Infect Dis 2004; 38: 311-20.
3. Cruciani M, de Lalla F, Mengoli C. Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and metaanalysis. Intensive Care Med 2005; 31: 1479-87.
4. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia: a matched case-control study. Arch Intern Med 1989; 149: 2349-53.
5. Menzin J, Meyers JL, Friedman M, et al. Mortality, length of hospitalization and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm 2009; 66: 1711-7.
6. Shorr AF, Gupta V, Sun X, Johannes RS, Spalding J, Tabak YP. Burden of early-onset candidemia: analysis of culture-positive bloodstream infections from a large US database. Crit Care Med 2009; 37: 2519-26.
7. Odds FC. Candida infections: an overview. Crit Rev Microbiol 1987; 15: 1-5.
8. Sudbery P, Gow N, Berman J. The distinct morphogenic states of Candida albicans. Trends Microbiol 2004; 12: 317-24.
9. Deslauriers N, Coulombe C, Carre B, Goulet JP. Topical application of a corticosteroid destabilizes the host-parasite relationship in an experimental model of the oral carrier state of Candida albicans. FEMS Immunol Med Microbiol 1995; 11: 45-55.
10. Scully C, El-Kabir M, Samaranayake LP. Candida and oral candidosis: a review. Crit Rev Oral Biol Med 1994; 5: 125-57.
11. Frohner IE, Bourgeois C, Yatsyk K, Majer O, Kuchler K. Candida albicans cell surface superoxide dismutases degrade host-derived reactive oxygen species to escape innate immune surveillance. Mol Microbiol 2009; 71: 240-52.
12. Carlisle PL, Banerjee M, Lazzell A, Monteagudo C, López-Ribot JL, Kadosh D. Expression levels of a filament-specific transcriptional regulator are sufficient to determine Candida albicans morphology and virulence. Proc Natl Acad Sci USA 2009; 106: 599-604.
13. Tronchin G, Pihet M, Lopes-Bezerra LM, Bouchara JP. Adherence mechanisms in human pathogenic fungi. Med Mycol 2008; 46: 749-72.
14. Phan QT, Myers C, Fu Y, Sheppard DC, et al. Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells. PLoS Biol 2007; 5: 543-57.
15. Schaller M, Borelli C, Korting HC, Hube B. Hydrolytic enzymes as virulence factors of Candida albicans. Mycoses 2005; 48: 365-77.
16. Naglik J, Albrecht A, Bader O, Hube B. Candida albicans proteinases and host/pathogen interactions. Cell Microbiol 2004; 6: 915-26.
17. Naglik JR, Challacombe SJ, Hube B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 2003; 67: 400-28.
18. Hube B, Naglik J. Candida albicans proteinases: resolving the mystery of a gene family. Microbiology 2001; 147: 1997-2005.
19. White TC, Miyasaki SH, Agabian N. Three distinct secreted aspartyl proteinases in Candida albicans. J Bacteriol 1993; 175: 6126-33.
20. White TC, Agabian N. Candida albicans secreted aspartyl proteinases: isoenzyme pattern is determined by cell type, and levels are determined by environmental factors. J Bacteriol 1995; 177: 5215-21.
21. Albrecht A, Felk A, Pichova I, et al. Glycosylphosphatidylinositolanchored proteases of Candida albicans target proteins necessary for both cellular processes and host-pathogen interactions. J Biol Chem 2006; 281: 688-94.
22. Odds F. Mycology in oral pathology. Acta Stomatol Belg 1997; 94: 75-80.
23. Nickerson KW, Atkin AL, Hornby JM. Quorum sensing in dimorphic fungi: farnesol and beyond. Appl Environ Microbiol 2006; 72: 3805-13.
24. Hornby JM, Jonsen EC, Lisec AD, et al. Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl Environ Microbiol 2001; 67: 2982-92.
25. Weber K, Sohr R, Schulz B, Fleischhacker M, Ruhnke M. Secretion of E,E-farnesol and biofilm formation in eight different Candida species. Antimicrob Agents Chemother 2008; 52: 1859-61.
26. Ramage G, Saville SP, Wickes BL, Lopez-Ribot JL. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl Environ Microbiol 2002; 68: 5459-63.
27. Jensen EC, Hornby JM, Pagliaccetti NE, Wolter CM, Nickerson KW, Atkin AL. Farnesol restores wild-type colony morphology to 96% of Candida albicans colony morphology variants recovered following treatment with mutagens. Genome 2006; 49: 346-53.
28. Braun PC. The effect of farnesol on amino acid incorporation by a wild-type and cell-wall variant strain of Candida albicans. Can J Microbiol 2005; 51: 715-8
29. Enjalbert B, Whiteway M. Release from quorum-sensing molecules triggers hyphal formation during Candida albicans resumption of growth. Eukaryot Cell 2005; 4: 1203-10.
30. Hornby JM, Nickerson KW. Enhanced production of farnesol by Candida albicans treated with four azoles. Antimicrob Agents Chemother 2004; 48: 2305-7.
31. Falkensammer B, Pleyer L, Ressler S, et al. Basidiomycete metabolites attenuate virulence properties of Candida albicans in vitro. Mycoses 2008; 51: 505-14.
32. Saidi S, Luitaud C, Rouabhia M. In vitro synergistic effect of farnesol and human gingival cells against Candida albicans. Yeast 2006; 23: 673-87.
33. Ausubel F M, Brent B, Kingston RE, et al. editors Current Protocols In Molecular Biology. New York, USA: John Wiley & Sons Inc.; 1994.
34. Naglik JR, Moyes D, Makwana J, et al. Quantitative expression of the Candida albicans secreted aspartyl proteinase gene family in human oral and vaginal candidiasis. Microbiology 2008; 154: 3266-80.
35. Vilanova M, Teixeira L, Caramalho I, et al. Protection against systemic candidiasis in mice immunized with secreted aspartic proteinase 2. Immunology 2004; 111: 334-42.
36. Mosel DD, Dumitru R, Hornby JM, Atkin AL, Nickerson KW. Farnesol concentrations required to block germ tube formation in Candida albicans in the presence and absence of serum. Appl Environ Microbiol 2005; 71: 4938-40.
37. Weber K, Schulz B, Ruhnke M. The quorum-sensing molecule E,E-farnesol-its variable secretion and its impact on the growth and metabolism of Candida species. Yeast 2010; 27: 727-39.
38. Joo JH, Jetten AM. Molecular mechanisms involved in farnesolinduced apoptosis. Cancer Lett. 2010; 287: 123-35.
39. Uppuluri P, Mekala S, Chaffin WL. Farnesol-mediated inhibition of Candida albicans yeast growth and rescue by a diacylglycerol analogue. Yeast 2007; 24: 681-93.
40. Davis-Hanna A, Piispanen AE, Stateva LI, Hogan DA. Farnesol and dodecanol effects on the Candida albicans Ras1-cAMP signalling pathway and the regulation of morphogenesis. Mol Microbiol 2008; 67: 47-62.
41. Shirtliff ME, Krom BP, Meijering RA, et al. Farnesol-induced apoptosis in Candida albicans. Antimicrob Agents Chemother 2009; 53: 2392-401.
42. Funari SS, Prades J, Escribá PV, Barceló F. Farnesol and geranylgeraniol modulate the structural properties of phosphatidylethanolamine model membranes. Mol Membr Biol 2005; 22: 303-11.
43. Rowat AC, Keller D, Ipsen JH. Effects of farnesol on the physical properties of DMPC membranes. Biochim Biophys Acta 2004; 1713: 29-39.
44. Bringmann A, Skatchkov S, Faude F, Enzmann V, Reichenbach A. Farnesol modulates membrane currents in human retinal glial cells. J Neurosci Res 2000, 62: 396-402.
45. Jabra-Rizk MA, Meiller T, James CE, Shirtliff ME. Effect of farnesol on Staphylococcus aureus biofilm formation and antimicrobial susceptibility. Antimicrob Agents Chemother 2006; 50: 1463-9.
46. Niewerth M, Kunze D, Seibold M, Schaller M, Korting HC, Hube B. Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors. Antimicrob Agents Chemother 2003; 47: 1807-17.
47. Le Lay C, Akerey B, Fliss I, Subirade M, Rouabhia M. Nisin Z inhibits the growth of Candida albicans and its transition from blastospore to hyphal form. J Appl Microbiol 2008; 105: 1630-9.
48. Hube B, Monod M, Schofield DA, Brown AJ, Gow NA. Expression of seven members of the gene family encoding secretory aspartyl proteinases in Candida albicans. Mol Microbiol 1994; 14: 87-99.
49. Lian CH, Liu WD. Differential expression of Candida albicans secreted aspartyl proteinase in human vulvovaginal candidiasis. Mycoses 2007; 50: 383-90.